Abstract

Problem: Unsuccessful reinnervation or neurofunctional recovery after recurrent laryngeal nerve injury may attribute to the loss of motoneurons in nucleus ambiguus. To assess the possibility of new drug therapy for injury of these motoneurons, we examined the neuroprotective effect of a novel neuroprotective compound, T-588 on the motoneuron loss in nucleus ambiguus after adult rat vagal nerve avulsion. Methods: The left vagal nerves of 12-week-old Sprague-Dawley rats were avulsed and removed at the level of jugular foramen. After the operation, the animals were freely administrated water containing 0.05% T-588 (Toyama Chemical Co Ltd, Toyama, Japan) solution. Four weeks after the operation, the number of surviving motoneurons in nucleus ambiguus was counted after Nissl staining to evaluate the neuroprotective effect of T-588. Results: In T-588-treated animals, a significantly larger number of surviving motoneurons in nucleus ambiguus was observed compared to control animals 4 weeks after the operation. Conclusion: Oral administration of T-588 after vagal nerve avulsion improved the survival of motoneurons in nucleus ambiguus. Significance: Oral administration of T-588 may prevent the degeneration of motoneurons in nucleus ambiguus in adult humans with recurrent laryngeal nerve injury, and could be a new treatment modality for recurrent laryngeal nerve paralysis. Support: None reported.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call